Voyager delays SOD1 ALS IND filing; switches payload after NHP data; cash runway to mid-2027

Voyager Therapeutics, Inc.

VY9323 IND/CTA filing no longer expected mid-2025 due to need for alternate payload after 3-month NHP data.
Capsid unchanged; decision based on achieving desired product profile for SOD1 ALS gene therapy.
Other programs unaffected: Neurocrine GBA1 and Friedreich’s ataxia IND filings still on track for 2025.
Tau silencing program VY1706 IND expected in 2026; preclinical activity levels achieved.
Cash and equivalents plus collaboration reimbursements fund operations into mid-2027.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.